The invention relates to the use of a compound of formula (I)

##STR00001##

or a salt thereof for combating animal pests,
where the symbols and indices are defined in the specification.

Compounds of formula (I) or formula (II) are disclosed:

##STR00001##

Wherein Y.sub.1, Y.sub.2 and Y.sub.3 are independently selected from CR.sub.1 or N. Such compounds find use as antibiotics and antifungals.

Compounds of formula (I) or formula (II) are disclosed:

##STR00001##

Wherein Y.sub.1, Y.sub.2 and Y.sub.3 are independently selected from CR.sub.1 or N. Such compounds find use as antibiotics and antifungals.

Embodiments of the disclosure relate to an organic light emitting element and a display device. Specifically, there may be provided an organic light emitting element including a compound represented by chemical formula 1 to provide excellent efficiency, long lifespan or low driving voltage and a display device including the organic light emitting element.

Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, geometrical isomer, prodrug, carboxylic acid isostere, solvate, polymorph, N-oxide, S-oxide or pharmaceutically acceptable salt thereof, which are GPR120 agonists. The present invention also relates to a pharmaceutical composition of a compound of formula (I) for the treatment of metabolic disorders, particularly Type 2 diabetes and associated diseases. ##STR00001##

The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, geometrical isomer, prodrug, carboxylic acid isostere, solvate, polymorph, N-oxide, S-oxide or pharmaceutically acceptable salt thereof, which are GPR120 agonists. The present invention also relates to a pharmaceutical composition of a compound of formula (I) for the treatment of metabolic disorders, particularly Type 2 diabetes and associated diseases. ##STR00001##

Provided are methods and/or systems to convert sulfide intermediates to sulfilimines using a series of continuous loop reactors instead of a batch reactor. The advantages of the methods and systems provided include improved total yield, improved heat management, improved phase mixing, and/or improved volume management.

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. ##STR00001##